Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 989

1.

Active surveillance for the management of prostate cancer in a contemporary cohort.

Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR.

Cancer. 2008 Jun 15;112(12):2664-70. doi: 10.1002/cncr.23502.

2.

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.

Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.

BJU Int. 2008 Jan;101(2):165-9. Epub 2007 Sep 10.

3.

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.

BJU Int. 2005 May;95(7):956-60.

4.

Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.

Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S.

Cancer. 2008 Jul 15;113(2):286-92. doi: 10.1002/cncr.23575.

5.

Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.

Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH.

Eur Urol. 2006 Sep;50(3):475-82. Epub 2006 May 3.

PMID:
16713065
6.

Prostate-specific antigen velocity in untreated, localized prostate cancer.

Venkitaraman R, Norman A, Woode-Amissah R, Dearnaley D, Horwich A, Huddart R, Parker C.

BJU Int. 2008 Jan;101(2):161-4. Epub 2007 Sep 10.

7.

Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.

Abouassaly R, Lane BR, Jones JS.

Urology. 2008 Apr;71(4):573-7. doi: 10.1016/j.urology.2007.11.094.

PMID:
18387385
8.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

9.

Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.

van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH.

BJU Int. 2009 Jun;103(11):1472-7. doi: 10.1111/j.1464-410X.2008.08281.x. Epub 2009 Jan 19.

10.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041. Epub 2010 May 15.

PMID:
20478589
11.

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators.

J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15.

PMID:
18707731
12.

Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.

van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH.

BJU Int. 2010 Apr;105(7):956-62. doi: 10.1111/j.1464-410X.2009.08887.x. Epub 2009 Oct 8.

13.
14.
15.

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.

Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW.

J Clin Oncol. 2003 Nov 1;21(21):4001-8.

PMID:
14581423
16.

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Carter HB, Walsh PC, Landis P, Epstein JI.

J Urol. 2002 Mar;167(3):1231-4.

PMID:
11832703
17.

Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.

Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS.

BJU Int. 2013 Mar;111(3):396-403. doi: 10.1111/j.1464-410X.2012.11295.x. Epub 2012 Jun 15.

18.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
19.

Are prostatic biopsies necessary in men aged > or =80 years?

Bott SR, Foley CL, Bull MD, Reddy CC, Freeman A, Montgomery BS, Langley SE.

BJU Int. 2007 Feb;99(2):335-8.

PMID:
17326264
20.

Supplemental Content

Support Center